|Bid||60.65 x 900|
|Ask||61.68 x 4000|
|Day's range||60.81 - 61.27|
|52-week range||52.83 - 66.41|
|PE ratio (TTM)||106.22|
|Earnings date||27 Jul 2018|
|Forward dividend & yield||1.92 (3.10%)|
|1y target est||69.06|
General Electric will replace Walgreens Boots Alliance Inc., as one of the 30 components of the 122-year-old Dow Jones Industrial Average. Here’s what that means for one of the oldest equity benchmarks.
A takeover bid by JCDecaux and a profit warning from U.K. housebuilder Berkeley are Wednesday’s corporate highlights in Europe.
Sanofi (SASY.PA) missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche (ROG.S) to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.
At first blush, HPV vaccines and Chinese rice wine don’t have much in common. For a start, shares in both have been on a tear. Kweichow Moutai is up 65 percent over the past 12 months, while Zhifei Biological, Merck & Co.’s exclusive sales agent in China, has risen 135 percent. The China Food and Drug Administration has accelerated approvals for new vaccines: While Merck’s Gardasil, which protects against four strains of human papilloma virus, took 1,421 days to get the nod, Gardasil 9, which protects against nine types of HPV, got the regulatory stamp from Beijing in just eight days.
Merck & Company (MRK) reported revenue of $10.0 billion in the first quarter, a rise of ~6% year-over-year, and GAAP (generally accepted accounting principles) EPS of $0.27 compared to net revenue of $9.4 billion and GAAP EPS of $0.56 in the first quarter of 2017.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Merck & Co Inc. (NYSE:MRK) is currently trading at a trailing P/E of 107.7x, which is higher than the industry average of 23.5x. Although some investors may jump to theRead More...
Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.
Medical tourism has been a great business for Manna Wang, an insurance agent in Shenzhen who’s been helping Chinese women travel to Hong Kong for a vaccine against the human papillomavirus, or HPV, which can cause cervical cancer. In the two years since Merck & Co.’s Gardasil 9 became available in Hong Kong, about 2 million mainlanders have come for the shots, according to the Xinhua News Agency. With the drugmaker unable to keep up, some clinics are turning away Chinese patients, and angry mainlanders have protested at Merck’s local office.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma , or who have relapsed after two or more prior lines of therapy.
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), the company’s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for GARDASIL 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine. “Women and men ages 27 to 45 continue to be at risk for acquiring HPV, which can lead to cervical cancer and certain other HPV-related cancers and diseases,” said Dr. Alain Luxembourg, director, clinical research, Merck Research Laboratories.
Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 as determined by an FDA-approved test.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
Walking around the convention floor at BIO was a remarkable experience this week in Boston. Not only were there an endless number of human health companies present, there were also animal health companies. States like Georgia, New Jersey, Maryland, Hawaii were also present, and countries too, among them Estonia, Japan, Switzerland, and Canada was a major sponsor of this year’s conference. The message at BIO was clear: The world needs biotech.
The Zacks Analyst Blog Highlights: Merck, Occidental Petroleum, Capital One Financial, Kimberly-Clark and Allstate
Headquartered in Thousand Oaks, California, Amgen (AMGN) is a biotechnology company. It discovers, develops, and delivers drugs for therapeutic areas including cardiovascular, neuroscience, and oncology.